The United Kingdom and the United States have agreed to a key bilateral deal that will keep no import taxes on UK pharmaceutical shipments going into the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has pledged to boost spending on medicines through the public health system. This move ensures that tariffs on these vital products will be held at zero for a timeframe of three years.
This agreement follows previous statements to hike import taxes on branded drug imports, with increases mentioned reaching 100%.
"This arrangement between the UK reinforces the international landscape for innovative medicines and introduces long-overdue equity to American-British pharmaceutical trade," an announcement noted.
Trade Significance
Pharmaceuticals represent one of the UK's largest goods shipped to the America, which is easily the largest destination for leading British pharmaceutical firms.
Trade data indicate that in the one-year period to the end of the third quarter, the UK shipped drugs totaling over eleven billion pounds to the US. This figure represented nearly one-fifth of total UK exports in that timeframe.
"This deal secures jobs, stimulates capital expenditure and facilitates the UK to become a worldwide center for biotech and pharma," a minister remarked.
Key UK Commitments
The pact includes several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to double total health service expenditure on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount drug companies must return to the NHS to control costs will be limited at 15%. Last year, refunds exceeded twenty percent.
Broader Context
This agreement follows a long-running row between the drug companies and the UK government over drug pricing and approval rates.
This friction were exacerbated by assertions that American consumers were charged significantly more for the same drugs than patients in the UK and Europe.
Recently, several major drug company projects in the UK have been halted or scrapped, while major investments have been announced toward US facilities.
The Science Minister stated that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a percentage of its resources over the past decade.
